May 1st 2024
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Ixazomib Triplet Improves PFS in Relapsed Multiple Myeloma
April 30th 2016The all-oral triplet of ixazomib, lenalidomide, and dexamethasone improved progression-free survival by 5.9 months compared with lenalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.
Read More
Dr. Sagar Lonial on Treating Patients With Smoldering Multiple Myeloma
March 31st 2016Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses whether or not to treat patients with smoldering multiple myeloma (SMM), or asymptomatic myeloma.
Watch
Scientists Identify "Feed-Forward Loop" Involving Micro-RNA and Sp1 in Multiple Myeloma
January 29th 2016For the first time, scientists have identified a "feed-forward loop" consisting of a gene, micro-RNA, and transcription factor implicated in both multiple myeloma and Waldenstrom's macroglobulinemia, according to an article published this month in the Blood Cancer Journal.
Read More
Dr. Andrew Branagan on A New Flu Vaccine for Patients With Myeloma
January 6th 2016Branagan said in his study, which gave patients with myeloma a high-dose flu vaccine followed by a booster dose 30 days later, 66% of patients saw total serum protection from the ailment. he said previous efforts to vaccinate patients with myeloma has resulted in a 20% total serum protection.
Watch
Dr. Robert Z Orlowski on the Importance of the Phase III SWOG S0777 Trial
December 15th 2015Data from the trial shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.
Watch
Bortezomib Triplet Emerges as the New Standard of Care in Patients With Untreated Multiple Myeloma
December 14th 2015The SWOG S0777 trial data shows induction therapy with a triplet of bortezomib, lenalidomide, and dexamethasone improved both progression-free survival and overall survival over lenalidomide and dexamethasone alone in patients with untreated multiple myeloma.
Read More
Elotuzumab Benefits Level Out in 3-Year Myeloma Data
December 14th 2015A triplet of elotuzumab, lenalidomide, and dexamethasone produced sustained improvements in both progression-free survival and overall survival in patients with relapsed/refractory multiple myeloma, according to a 3-year analysis of the phase III ELOQUENT-2 trial.
Read More
Ixazomib Triplet Showcases PFS Increases in Myeloma
December 12th 2015An oral treatment combination of ixazomib, lenalidomide, and dexamethasone showed a 5.9-month improvement in progression-free survival in comparison to lenalidomide and dexamethasone alone for relapsed/refractory multiple myeloma.
Read More
New Data Suggests Role for CAR Treatment Post-Transplant in Advanced B-cell Cancers
December 12th 2015Gene therapy has potential to deliver lasting remissions in patients with advanced B-cell malignancies who have undergone allogeneic hematopoietic stem cell transplant, according to research presented by James N. Kochenderfer, MD.
Read More
Ruxolitinib Shines in New, Long-Term Myelofibrosis Data
December 6th 2015Data shows ruxolitinib continues to work in patients with advanced myelofibrosis by maintaining spleen size reduction and overall survival improvements over the course of a 5 year study, according to data presented during the 57th Annual Meeting of the American Society of Hematology.
Read More
Daratumumab Shows Rapid and Durable Responses in Patients With Multiple Myeloma
December 6th 2015Daratumumab demonstrated a 31% overall response rate as monotherapy for patients with heavily pretreated multiple myeloma, according to a combined analysis of two pivotal studies presented at the 2015 ASH Annual Meeting.
Read More
Ixazomib, Cyclophosphamide, Dexamethasone Combination Effective in Myeloma
December 5th 2015The triple combination of ixazomib, cyclophosphamide, and dexamethasone, all taken orally, showed encouraging early response rates in elderly patients with newly diagnosed multiple myeloma, according to phase II data presented at the 2015 ASH Annual Meeting.
Read More
Ixazomib Approved for Relapsed Multiple Myeloma by FDA
November 20th 2015A combination of the oral proteasome inhibitor ixazomib (Ninlaro), lenalidomide (Revlimid) and dexamethasone has been approved by the FDA a full 4 months ahead of schedule for patients with multiple myeloma with at least 1 prior surgery.
Read More
FDA Grants Priority Review to Carfilzomib for Relapsed Multiple Myeloma
September 21st 2015Carfilzomib (Kyprolis) in combination with dexamethasone, was recently granted a priority review designation by the FDA for patients who have relapsed multiple myeloma, following prior treatment with at least one therapy.
Read More
Ixazomib Granted Priority Review by the FDA for Multiple Myeloma
September 10th 2015Ixazomib (MLN9708), an oral proteasome inhibitor, was recently granted a priority review designation by the FDA, in combination with lenalidomide and dexamethasone for the treatment of patients who have relapsed and/or refractory multiple myeloma.
Read More
ELOQUENT-2 Study in Patients With Relapsed/Refractory Multiple Myeloma
August 17th 2015Sagar Lonial, MD, professor, School of Medicine, executive vice chair, Department of Hematology & Medical Oncology, chief medical officer, Winship Cancer Institute, Emory University, discusses the ELOQUENT-2 study in patients with relapsed/refractory multiple myeloma.
Watch